Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

Dynex Unveils Dynex Moonshots, Dedicated to Transformative Change Through Capital-Enhanced n.quantum Computing

Published

on

dynex-unveils-dynex-moonshots,-dedicated-to-transformative-change-through-capital-enhanced-n.quantum-computing

Global Thought Leaders Join Dynex Moonshots’ Ethical Committee, Strengthening Commitment to Ethical Integrity and Innovation

VADUZ, Liechtenstein, April 2, 2024 /PRNewswire/ — Dynex, the world’s only accessible neuromorphic quantum computing cloud for solving real-world problems at scale, proudly announces the launch of Dynex Moonshots, the investment, strategic, and ethical steward of the Dynex Ecosystem. Leveraging the endless innovative advancements made possible by Dynex n.quantum computing, Dynex Moonshots accelerates the global movement of transformative change for the betterment of our world and beyond.

Through global collaboration, a robust ethical framework, and access to capital, Dynex Moonshots is poised to transform industries and drive positive change on a global scale. Dynex Moonshots focuses on the advancement of society, nature, health, and space, and is open to any established business, research initiative or emerging ventures in need of harnessing the unparalleled capabilities of the Dynex n.quantum computing cloud, applying its power to confirm hypotheses swiftly and reducing time constraints. To apply for consideration, visit dynexmoonshots.org.

The work of Dynex Moonshots will be informed by its Ethical Committee, which is tasked with overseeing the ethical integrity of select Dynex n.quantum computing inquiries. The Ethical Committee’s role is critical to ensuring that activities under the purview of Dynex Moonshots adhere to the highest ethical standards and contribute positively to the future.

The Ethical Committee includes:

  • Daniela Herrmann – Co-Founder, Dynex, and Mission Leader, Dynex Moonshots. Investing in businesses that have global reach and significant impact, Hermann brings a wealth of experience in growing and scaling small and midsize companies set to change the future.
  • Sally Chu – An acclaimed World Women’s Organization award recipient, Chu is the founder of the Oneness Art Platform. She has a rich 30-year history in the art industry, with a vast network across Europe and Asia. With deep roots in HK/China and highly respected by the community, Chu is well-versed in bridging the art and business worlds. From accounts to manuscripts, she sees art as a channel that offers glimpses of the deeper truth. Her expertise spans beyond art curation at Chu’s Gallery to encompass life coaching and spiritual healing. Oneness Platform merges classical and virtual art, rituals and digital reality, charity and spiritual lifestyle, profoundly impacting both local and international communities.
  • Dr. Mikael Lind – Adjunct Professor in Maritime Informatics. Dr. Lind contributes to forums such as the World Economic Forum, Europe’s DTLF, and UN/CEFACT, and his pioneering work in maritime informatics, supply chain resilience, and maritime decarbonization has helped shape the future of sustainable transport.
  • Wolfgang Lechmacher – Independent global expert in supply chain and logistics; former Director, Head of Supply Chain and Transport Industries for the World Economic Forum. Lehmacher’s publications impact the thinking of the world’s decision-makers, and he provides advice to public and private sector actors as an executive advisor, and member of boards, think tanks, and expert committees across the globe.
  • Sharron L. McPherson – Adjunct Professor in Project Finance at the University of Cape Town’s Graduate School of Business, Member of the Faculty of Singularity University (NASA Ames), and Senior Fellow (Climate Resilience) at the Stimson Center in Washington, D.C. McPherson has over 30 years of experience starting, building, and navigating businesses through competitive and complex regulatory environments.
  • Dr. Chris Luebkeman – World renowned futurist, Head of the Strategic Foresight Hub at ETH Zurich and founder of [y]our2040. His career spans disciplines, geographies and cultures. His work in digital transformation and futures thinking at the University of Oregon and MIT led him to Arup in London, where he founded the Foresight, Innovation, and Incubation teams.

“Dynex Moonshots represents a new frontier in ethical innovation, where cutting-edge technology meets unwavering ethical principles,” said Daniela Herrmann, Co-Founder of Dynex and Mission Leader, Dynex Moonshots. “Through collaboration, integrity, and vision, Dynex Moonshots is poised to redefine what is possible and leave a lasting impact on the world and beyond.”

For more information, please visit dynexmoonshots.org.

About Dynex:            
Dynex is the world’s only accessible neuromorphic computing cloud for solving real-world problems, at scale. The company began as an informal project with collaboration amongst a community of extraordinary minds and quickly evolved into a technological leader ready to scale into global markets. The Dynex n.quantum computing cloud performs quantum computing based algorithms without limitation, executing calculations with unparalleled speed and efficiency, surpassing usual quantum computing constraints. Dynex is dedicated to pushing the boundaries of technology to create sustainable, secure, and innovative solutions that address complex challenges and drive progress, solving real world problems.

Press Contact:
[email protected]

Logo – https://mma.prnewswire.com/media/2376715/Transparent__Dynex_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/dynex-unveils-dynex-moonshots-dedicated-to-transformative-change-through-capital-enhanced-nquantum-computing-302105756.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024

Published

on

invitation-to-presentation-of-eqt-ab’s-q1-announcement-2024

STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826

The following files are available for download:

https://mb.cision.com/Main/87/3956826/2712771.pdf

Invitation to presentation of EQT AB’s Q1 Announcement 2024

https://news.cision.com/eqt/i/eqt-ab-group,c3285895

EQT AB Group

 

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs

Published

on

kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs
  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Published

on

biovaxys-technology-corp.-provides-bi-weekly-mcto-status-update

VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html

Continue Reading
Advertisement
Advertisement

Latest news

Trending